Yes the call, created more questions than answers, but I think the key takeaway here for a short time frame catalyst is the UK EAMS potential. I would not be surprised to see this happen and maybe faster than we're expecting. What Kush described fits Leron's position, and it sounds like the idea is coming from MHRA.. they are telling us they was to do EAMS, no!?!

I posted this one yesterday but it deserves repeating:

“MHRA has recommended that Leronlimab might be a good candidate for Early access to Medicines Scheme or called EAMS. Under this EAMS approval patients in the UK will be allowed to have access to #leronlimab prior to it’s full marketing authorization."

I'm going to listen to that section again, but didn't Kush say they are already putting together for delivery everything MHRA has asked for to make a determination here? Given our safety profile the UK may just bang this out, to all our surprise.